

# Four-factor prothrombin complex concentrates outcomes in surgery and major bleed

<b>Submission date</b> 14/12/2023	<b>Recruitment status</b> Recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 29/01/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 17/02/2026	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

In the event of surgery or a major bleed, where temporary interruption with blood-thinning medication can no longer be used, agents like 4F-PCC can reverse the effects of the blood-thinning medications. Medications such as PROTHROMPLEX TOTAL and 4F-PCC are medications which are generally used to quickly reverse the effects of a blood-thinning medicine during a major bleed, or when there is a need for surgery. The aim of this study is to fill the knowledge gaps of PROTHROMPLEX TOTAL and 4F-PCC treatments in patients presenting for surgery or a major bleed.

### Who can participate?

Patients aged 18 years and over who had a surgery or a bleeding episode and were receiving a blood-thinning medication and medications such as PROTHROMPLEX TOTAL or another 4-factor prothrombin complex concentrate (4F-PCC) to reverse the effect of the blood-thinning medication.

### What does the study involve?

This is a retrospective chart review study in which the healthcare team at the study site will review patient medical records and collect unidentifiable health information for inputting into a database.

### What are the possible benefits and risks of participating?

As this is an observational study, participants will not experience additional risks. Participants will receive no direct individual benefit from participation in this study. The only potential benefit is a better understanding of the use of medications such as PROTHROMPLEX TOTAL or another 4-factor prothrombin complex concentrate (4F-PCC).

### Where is the study run from?

Takeda Development Center Americas, Inc. (USA)

### When is the study starting and how long is it expected to run for?

June 2022 to May 2026

Who is funding the study?  
Takeda Development Center Americas, Inc. (USA)

Who is the main contact?  
Angela Simon, Angela.simon@takeda.com

## Contact information

### Type(s)

Public, Principal investigator

### Contact name

Dr Nidhi Guatam

### Contact details

Watford General Hospital  
60 Vicarage Road  
Watford  
United Kingdom  
WD18 OHB  
+44 (0)1923670029  
nidhi.gautam@nhs.net

### Type(s)

Scientific

### Contact name

Ms Angela Simon

### Contact details

Takeda Development Center Americas, Inc.  
95 Hayden Avenue  
Lexington  
United States of America  
02421  
+1 (0)248 990 2390  
Angela.simon@takeda.com

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### Integrated Research Application System (IRAS)

331744

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number

TAK-330-5002

## Central Portfolio Management System (CPMS)

56352

# Study information

### Scientific Title

A retrospective chart review study evaluating clinical practice, treatment patterns and outcomes of four-factor prothrombin complex concentrates (4F-PCC) in patients treated with Factor Xa (FXa) inhibitors prior to surgery or invasive procedure and those requiring on-demand reversal for a major bleed

### Acronym

TAK-330

### Study objectives

This study aims to fill knowledge gaps of four-factor prothrombin complex concentrates (4F-PCC) reversal interventions among patients presenting for surgery or a major bleed who are treated with a Factor Xa inhibitor.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

approved 11/11/2023, East Midlands - Leicester South Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8143; leicestersouth.rec@hra.nhs.uk), ref: 23/EM/0261

### Study design

Retrospective non-interventional multinational multicenter hospital chart review study

### Primary study design

Observational

### Study type(s)

Other

### Health condition(s) or problem(s) studied

Blood loss, surgical

### Interventions

Data will be collected from the patient's medical records during the pre-treatment period (prior to receiving the first 4F-PCC dose) and post-treatment period (30-90 days after the first 4F-PCC dose). This data from the medical records will be collected based on the routine treatment that this patient is receiving, without any additional tests, procedures, or treatments.

### Intervention Type

Other

## **Primary outcome(s)**

### **Surgery indication:**

1. Intra-operative hemostatic effectiveness will be regarded as effective or ineffective based on a review of intraoperative documentation
2. Post-operative hemostatic effectiveness within 24 hours after index 4F-PCC infusion will be regarded as effective or ineffective based on a review of postoperative documentation. Absence of post-operative bleeding or oozing will be classified as effective hemostasis.

### **Bleeding indication:**

Hemostatic effectiveness will be measured using the International Society on Thrombosis and Haemostasis (ISTH) criteria, Modified Sarode Criteria, Glasgow Coma Score or NIH Stroke Scale (NIHSS) score within 1 hour, 6 hours, and 24 hours of 4F-PCC infusion.

### **Change in clinical status over time will be measured using:**

1. American College of Surgeons Advanced Trauma Life Support (ATLS) classification of blood loss based on the following signs and symptoms within 1, 6, and 24 hours of index 4F-PCC infusion
2. Clinical opinion based on progress notes for evidence of a change in: a) clinical status and b) amount of bleeding within 1, 6, and 24 hours of index 4F-PCC infusion as worse, no-change (stable), better, or undocumented will be captured for every type of bleed and recurrence of bleeding at the same site as the initial bleed prior to discharge

All outcome measures are collected retrospectively from medical charts

## **Key secondary outcome(s)**

As this is an exploratory study, there are no key secondary outcomes that are powered to address any predefined hypothesis. Secondary outcomes data is abstracted from patient chart data.

The secondary objectives are as follows:

### **Surgery indication:**

1. Baseline characteristics, including FXa inhibitor type, dose, and time of last FXa inhibitor dose prior to procedure, anti-FXa level and assay type (calibrated) indication for anticoagulation, concurrent antiplatelet, anticoagulant, prothrombotic and fibrinolytic therapy, and comorbidities of patients who require 4F-PCC reversal therapy of FXa inhibitor anticoagulation during surgical/interventional procedures.
2. Clinical practice patterns, including procedure type, reversal agent administration characteristics (e.g., administration method [IV push, bolus, infusion], dose, concentration, time between reversal agent infusion and initiation of surgery, use of additional doses of reversal agents, and time of administration), use of other interventions for control of hemostasis, i.e., transfusions (e.g., PRBC, FFP transfusions), other pharmacological agents and invasive procedures, reinitiation of anticoagulant therapy within 30-days of index 4F-PCC infusion (type of anticoagulant, dose, time of re-initiation), and method used to monitor anticoagulant therapy (no monitoring, PT, TT, aPTT, anti-FXa assay, ecarin clotting time [ECT], thrombin generation assay [TGA]).

### **Bleeding indication:**

1. Baseline characteristics, including FXa inhibitor type, dose, and time of last FXa inhibitor dose, Anti-FXa level prior to 4F-PCC infusion, indication for anticoagulation, concurrent antiplatelet, anticoagulant, prothrombotic and fibrinolytic therapy, Glasgow Comma Score, intracerebral hemorrhage (ICH) hematoma volume, and comorbidities of patients who require 4F-PCC reversal

therapy of FXa inhibitor anticoagulation for acute major bleeds

2. Clinical practice patterns, including type and location of bleed, reversal agent administration characteristics (e.g., administration method [IV push, bolus, infusion] dose, concentration, use of additional doses of reversal agents, and time of administration), use of other interventions for control of hemostasis, i.e., transfusions, other pharmacological agents and invasive procedures, re-initiation of anticoagulant therapy within 30 days of on-demand 4F-PCC treatment (type of anticoagulant, dose, time of re-initiation), method used to monitor anticoagulant therapy (no monitoring, PT, TT, aPTT, anti-FXa assay, ECT, TGA)

All outcome measures are collected retrospectively from medical charts

### **Completion date**

29/05/2026

## **Eligibility**

### **Key inclusion criteria**

Surgery indication:

1. Patient was >18 years of age at the time of surgery/invasive procedure
2. Patient was on treatment with an oral FXa inhibitor (rivaroxaban, apixaban, edoxaban) at time of surgery/invasive procedure
3. Patient admitted for a high-bleeding risk surgery (e.g., intra-abdominal surgery [e.g., bowel or visceral organ resection]), intra-thoracic surgery (e.g., lung resection), major orthopedic surgery (e.g., hip/knee replacement), arterial revascularization (e.g., abdominal aortic aneurysm repair, vascular bypass), urologic surgery (e.g., prostatectomy, bladder tumor resection), any other surgery lasting  $\geq 1$  hour, or major invasive procedure with high bleeding risk (e.g., colonic polyp resection, biopsy of kidney or prostate)
4. Patient received Takeda PROTHROMPLEX TOTAL or other 4F-PCC (e.g., Beriplex/Kcentra, Octaplex, Cofact, Uman Complex, Kanokad, Kedcom) reversal infusion during surgery or an invasive procedure as their first reversal agent type to control intra-operative bleeding in patients admitted for surgery/invasive procedure

Major bleed indication:

1. Patient was >18 years of age at time of admission for an acute major bleed
2. Patient was on treatment with an oral FXa inhibitor (rivaroxaban, apixaban, edoxaban) at the time of major bleed
3. Patient received a 4F-PCC reversal infusion (e.g., Beriplex/Kcentra, Octaplex, PROTHROMPLEX TOTAL, Cofact, Uman Complex, Kanokad, Kedcom) for a major bleed as their first on-demand reversal agent type
4. Acute major bleeding, defined as bleeding that is potentially life-threatening, that requires an emergent surgery or invasive procedure, or requires transfusion of  $\geq 1$  units of PRBCs or is associated with a decrease in Hg of  $>2.0$  g/dL, or bleeding in a critical area or organ such as intraspinal, pericardial, or intracranial. Acute bleeding associated with a Hg level of  $\leq 8$  g/dL if no baseline Hg is available is also considered major.

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

100 years

**Sex**

All

**Total final enrolment**

0

**Key exclusion criteria****Surgery indication:**

Cohort 1: Real-world patients undergoing reversal with 4F-PCC

1. Patient presented with an acute bleed that required on-demand therapy with 4F-PCC
2. Patient underwent a low-bleeding risk surgery/invasive procedure (gastrointestinal endoscopy [with or without biopsy], cardiac catheterization [with or without percutaneous coronary intervention], permanent pacemaker or internal defibrillator insertion, dental surgery or other dental procedure, dermatologic surgery or other dermatologic procedure, cataract removal or other ophthalmologic procedure, any other surgery or procedure lasting < 1 hour)
3. Participation in a clinical study involving an investigational product or device within 30 days prior to or after initiation of 4F-PCC reversal

**Bleeding indication:**

Cohort 2: Real-world patients undergoing on-demand reversal with 4F-PCC for major bleeding

1. Patient with acquired/congenital hemostatic disorders, e.g., hemophilia A and B, platelet function disorder, fibrinogen deficiency, Von Willebrand disease, coagulation factor deficiency, acute or chronic liver failure (hepatic cirrhosis Child-PUGH score C (1)), confirmed or suspected sepsis
2. Patient with minor bleeding (e.g., epistaxis, hematuria)
3. Peri-operative reversal with 4F-PCC to control intra-operative bleeding in patients admitted for surgery/invasive procedure
4. Participation in a clinical study within 30 days post initiation of 4F-PCC on-demand reversal

**Date of first enrolment**

01/01/2024

**Date of final enrolment**

30/04/2026

**Locations****Countries of recruitment**

United Kingdom

England

Austria

Belgium

Germany

Greece

Netherlands

Poland

Spain

**Study participating centre**

**West Hertfordshire Teaching Hospitals NHS Trust**

Trust Offices

Watford General Hospital

Vicarage Road

Watford

England

WD18 0HB

**Study participating centre**

**West Suffolk NHS Foundation Trust**

West Suffolk Hospital

Hardwick Lane

Bury St. Edmunds

England

IP33 2QZ

## **Sponsor information**

**Organisation**

Takeda (United States)

**ROR**

<https://ror.org/03bygaq51>

## **Funder(s)**

**Funder type**

Not defined

**Funder Name**

Takeda Development Center Americas, Inc.

**Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Data sharing statement to be made available at a later date